For example, TAMs also recruited CD8+ T cells that solely expressed NKG2A via the CXCL16-CXCR6 pathway, leading to anti-PD-1 resistance in GC patients (Li G. et al., 2024), supporting the potential of NKG2A as a novel immunotherapeutic target and present fresh perspectives on combination strategies involving ICIs in GC (Li G. et al., 2024). Here, CXCL16 is linked to gastric cancer.